myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)
NICE has developed a medtech innovation briefing (MIB) on myCOPD for self-management of chronic obstructive pulmonary disease
Search results
111 results
-
-
COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 (ES24)
ES24 Key messages The content of this evidence review was up-to-date on
-
COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis (ES26)
ES26 Key messages The content of this evidence review was up-to-date on 13 May 2020. See summaries of product characteristics (SPCs)
-
COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES25)
ES25 Key messages The content of this evidence review was up-to-date on 20 April 2020. See summaries of product characteristics
-
COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES23)
COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19
-
Antimicrobial prescribing: meropenem with vaborbactam (ES21)
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
-
Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia (ES22)
Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated
-
COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)
ES27 Key messages The content of this evidence review was up-to-date on 4 June 2020. See summaries of product characteristics
-
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis
-
COVID-19 rapid evidence summary: vitamin D for COVID-19 (ES28)
ES28 Key messages The content of this evidence summary was up-to-date on 18 June 2020. See summaries of product characteristics
-
DyeVert for reducing contrast media in coronary and peripheral angiography (MIB196)
NICE has developed a medtech innovation briefing (MIB) on DyeVert for reducing contrast media in coronary and peripheral angiography
-
Archimedes for biopsy of suspected lung cancer (MIB211)
NICE has developed a medtech innovation briefing (MIB) on Archimedes for biopsy of suspected lung cancer
-
TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation (MIB210)
NICE has developed a medtech innovation briefing (MIB) on TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation
-
Lifelight First for monitoring vital signs (MIB213)
NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs
-
Space from Depression for treating adults with depression (MIB215)
NICE has developed an Improving Access to Psychological Therapies (IAPT) report on Space from Depression for treating adults with depression
-
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19
-
Cor-Knot for tying suture knots in valve surgery (MIB206)
NICE has developed a medtech innovation briefing (MIB) on Cor-Knot for tying suture knots in valve surgery
-
Artificial intelligence for analysing CT brain scans (MIB207)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans
-
NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds (MIB208)
NICE has developed a medtech innovation briefing (MIB) on NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wound
-
EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules (MIB209)
NICE has developed a medtech innovation briefing (MIB) on EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules
-
Plus Sutures for preventing surgical site infection (MIB204)
NICE has developed a medtech innovation briefing (MIB) on Plus Sutures for preventing surgical site infection
-
Actim Pancreatitis for diagnosing acute pancreatitis (MIB218)
NICE has developed a medtech innovation briefing (MIB) on Actim Pancreatitis for diagnosing acute pancreatitis
-
FibroScan for assessing liver fibrosis and cirrhosis in primary care (MIB216)
NICE has developed a medtech innovation briefing (MIB) on FibroScan for assessing liver fibrosis and cirrhosis in primary care
-
Healthy.io test for home testing of urine albumin to creatinine ratio (MIB221)
NICE has developed a medtech innovation briefing (MIB) on Healthy.io test for home testing of urine albumin to creatinine ratio
-
Synergo for non-muscle-invasive bladder cancer (MIB226)
NICE has developed a medtech innovation briefing (MIB) on Synergo for non-muscle-invasive bladder cancer
-
Helge for detecting haemolysis (MIB225)
NICE has developed a medtech innovation briefing (MIB) on Helge for detecting haemolysis
-
Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome (MIB223)
NICE has developed a medtech innovation briefing (MIB) on Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome
-
AmnioSense for unexplained vaginal wetness in pregnancy (MIB198)
NICE has developed a medtech innovation briefing (MIB) on AmnioSense for unexplained vaginal wetness in pregnancy
-
Optowire for measuring fractional flow reserve (MIB199)
NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve
-
PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection (MIB200)
NICE has developed a medtech innovation briefing (MIB) on PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak
-
eXroid for internal haemorrhoids (MIB201)
NICE has developed a medtech innovation briefing (MIB) on eXroid for internal haemorrhoids
-
PulmoVista 500 for monitoring ventilation in critical care (MIB203)
NICE has developed a medtech innovation briefing (MIB) on PulmoVista 500 for monitoring ventilation in critical care
-
Prontosan for acute and chronic wounds (MIB220)
NICE has developed a medtech innovation briefing (MIB) on Prontosan for acute and chronic wounds
-
MolecuLight i:X for wound imaging (MIB212)
NICE has developed a medtech innovation briefing (MIB) on MolecuLight i:X for wound imaging
-
Novii Wireless Patch System for maternal and fetal monitoring (MIB228)
NICE has developed a medtech innovation briefing (MIB) on Novii Wireless Patch System for maternal and fetal monitoring
-
pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms (MIB222)
NICE has developed a medtech innovation briefing (MIB) on pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms
-
t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes (MIB227)
NICE has developed a medtech innovation briefing (MIB) on t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes
-
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)
NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic
-
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)
NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing
-
AnaConDa-S for sedation with volatile anaesthetics in intensive care (MIB229)
NICE has developed a medtech innovation briefing (MIB) on AnaConDa-S for sedation with volatile anaesthetics in intensive care
-
LQD Spray for treating acute and chronic wounds (MIB202)
NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds
-
Leukomed Sorbact for preventing surgical site infection (MIB197)
NICE has developed a medtech innovation briefing (MIB) on Leukomed Sorbact for preventing surgical site infection
-
National Early Warning Score systems that alert to deteriorating adult patients in hospital (MIB205)
NICE has developed a medtech innovation briefing (MIB) on National Early Warning Score systems that alert to deteriorating adult patients in hospital
-
The percentage of patients with COPD and Medical Research Council (MRC) Dyspnoea Scale ≥3 at any time in the preceding 15 months, with a subsequent record of an offer of referral to a pulmonary rehabilitation programme
NICE indicators. NM47 COPD guidance.
-
The percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or dementia who have been screened for hazardous drinking using the FAST or AUDIT-C tool in the preceding 2 years.
The percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or...
-
The percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or dementia with a FAST score of ≥3 or AUDIT-C score of ≥5 in the preceding 2 years who have received brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded
The percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or...
-
The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses aged 25-84 (excluding those with pre-existing CHD, diabetes, stroke and/or TIA) who have had a CVD risk assessment performed in the preceding 12 months (using an assessment tool agreed with NHS England)
The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses aged 25-84 (excluding those with pre-existing CHD,...
-
The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a comprehensive care plan documented in the record, in the preceding 12 months, agreed between individuals, their family and/or carers as appropriate (Inherited)
The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a comprehensive care plan documented in the...
-
The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of alcohol consumption in the preceding 15 months
NICE indicators. NM15 schizophrenia guidance.
-
The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood pressure in the preceding 15 months
NICE indicators. NM17 schizophrenia guidance.